Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Candi5V01 A FTIH Phase I/II Randomized and Controlled Study to Test Safety, Immunogenicity and Preliminary Efficacy of a Pentavalent Bioconjugate Vaccine (Candi5V) Against Candida in Women With Recurrent Vulvovaginal Candidiasis.

NCT06190509 is registered in ClinicalTrials.gov with LimmaTech Biologics AG as lead sponsor.

NCT NCT06190509
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06190509 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Candi5V01 A FTIH Phase I/II Randomized and Controlled Study to Test Safety, Immunogenicity and Preliminary Efficacy of a Pentavalent Bioconjugate Vaccine (Candi5V) Against Candida in Women With Recurrent Vulvovaginal Candidiasis.
Lead sponsor
LimmaTech Biologics AG
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
December 6, 2023
Completion date
April 30, 2027
Enrollment
251 (estimated)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

recurrent vulvovaginal candidiasis